NEW YORK (GenomeWeb) – The New York State Department of Health has approved Counsyl's noninvasive prenatal screen, Prelude, which can be run as early as 10 weeks into gestation to determine the risk of fetal chromosomal aneuploidies that can cause Down syndrome and other conditions, the company announced today.

The South San Francisco, California-based genetic testing firm uses next-generation sequencing to analyze circulating cell-free DNA in maternal blood, as well as custom algorithms and bioinformatics tools.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.